Valneva (NASDAQ:VALN) Releases Earnings Results, Misses Expectations By $0.17 EPS

Valneva (NASDAQ:VALN) released its quarterly earnings results on Friday. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.17), Zacks reports. The company had revenue of $39.37 million for the quarter, compared to analyst estimates of $43.15 million. Valneva had a negative return on equity of 107.63% and a negative net margin of 88.87%.

Valneva Trading Up 26.2%

Shares of NASDAQ:VALN traded up $1.48 during mid-day trading on Friday, reaching $7.13. 2,800,516 shares of the company were exchanged, compared to its average volume of 68,534. Valneva has a 1 year low of $4.75 and a 1 year high of $12.25. The company has a debt-to-equity ratio of 2.14, a current ratio of 2.14 and a quick ratio of 1.60. The firm’s 50-day simple moving average is $5.21 and its 200 day simple moving average is $6.92. The firm has a market cap of $676.38 million, a price-to-earnings ratio of -3.81 and a beta of 1.77.

Valneva News Summary

Here are the key news stories impacting Valneva this week:

• Positive Sentiment: EMA review begins for Lyme vaccine: Pfizer and Valneva announced that the European Medicines Agency validated their marketing authorization application for the six-valent OspA-based Lyme disease vaccine candidate, PF-07307405. Validation means the application is complete and can enter formal regulatory assessment—an important milestone, though it does not guarantee approval. Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
• Positive Sentiment: Potentially large commercial opportunity: Coverage highlights the long-awaited development of a Lyme disease vaccine and suggests European regulatory decisions could come within roughly 12 months. A successful product could provide Valneva with a major new revenue stream through its partnership with Pfizer. EU to study potential vaccine for Lyme disease: companies
• Positive Sentiment: 2026 outlook reaffirmed: Valneva maintained its full-year financial guidance while outlining its strategic priorities and continued focus on its vaccine portfolio. This provides some reassurance despite quarterly results falling short of expectations. Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates
• Neutral Sentiment: New analyst coverage: TD Cowen initiated research coverage of Valneva. The available report does not specify a rating or price target, limiting its immediate investment significance. Valneva Research Coverage Started at TD Cowen
• Negative Sentiment: Quarterly results missed estimates: Valneva reported a loss of $0.40 per share versus the expected $0.23 loss, while revenue of $39.37 million was below the $43.15 million consensus. The company continues to report substantial net losses and negative return on equity, underscoring execution and funding risks. Valneva Earnings Results

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on VALN. The Goldman Sachs Group lowered Valneva from a “neutral” rating to a “sell” rating and set a $4.90 price objective on the stock. in a report on Wednesday, April 22nd. TD Cowen initiated coverage on shares of Valneva in a report on Tuesday. They set a “buy” rating and a $12.00 target price for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Valneva in a research report on Thursday, June 18th. Guggenheim set a $11.00 price target on shares of Valneva in a research note on Thursday, April 16th. Finally, Wall Street Zen upgraded shares of Valneva from a “strong sell” rating to a “sell” rating in a research report on Monday, June 1st. Four analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $11.98.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Marex Group plc acquired a new stake in shares of Valneva in the second quarter valued at $64,000. JPMorgan Chase & Co. purchased a new stake in shares of Valneva in the 3rd quarter valued at $124,000. Finally, XTX Topco Ltd acquired a new position in Valneva during the 4th quarter worth about $94,000. 11.39% of the stock is currently owned by institutional investors and hedge funds.

About Valneva

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.